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Background: The ALDH18A1 gene is located at 10q24.1 and encodes delta-1-pyrroline-5-carboxylate synthetase (P5CS), a mito-
chondrial bifunctional enzyme that catalyzes the first two steps in de novo biosynthesis of proline, ornithine, citrulline, and arginine.
ALDH18A1-related disorders have been classified into four groups, such as autosomal dominant and recessive hereditary spastic
paraplegia (SPG9A and SPG9B, respectively), as well as autosomal dominant and recessive cutis laxa (ADCL3 and ARCL3A,
respectively). Neurodegeneration is a characteristic feature of all groups.
Case report: Here, we report a girl with compound heterozygous disease-causing variants (c.-28-2A>G and c.383G>A, p.
Arg128His) in the ALDH18A1 gene, revealed by whole exome sequencing. The c.-28-2A>G variant in intron 1, inherited from
the mother, is a novel mutation, while the c.383G>A variant in exon 4, inherited from the father, has already been reported.
The patient presented with vigorous infantile tremor preceding progressive spastic paraplegia. Dysmorphic features included elon-
gated face, deep-set ears, upturned nose, long philtrum and pointed chin. Intrauterine and postnatal growth retardation, micro-
cephaly, global developmental delay and profound intellectual disability were also noticed. Blood fasting ammonia level, plasma
proline, ornithine and arginine levels were normal, while citrulline level was slightly decreased. Brain MRI revealed moderate hypo-
plasia of the corpus callosum and reduction of white matter volume.
Conclusions: The patient represents SPG9B, a rare form of autosomal recessive hereditary spastic paraplegias. The early onset
tremor, preceding lower limb spasticity appears to be a unique early manifestation of neurodegeneration in this case.
 2020 The Japanese Society of Child Neurology. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Monoallelic and biallelic mutations in ALDH18A1
(OMIM 138250), located at 10q24.1, can cause neu-
rodegeneration in association with various non-
neurological features [1–3]. Based on genotypic and phe-
notypic features the ALDH18A1-related disorders have
been classified into four groups, such as autosomal dom-
inant and recessive hereditary spastic paraplegia
(SPG9A, OMIM 601162 and SPG9B, OMIM 616586,lsevier B.V.
commons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Photos and MR images of the patient. The patient at the age of
2.5 years (A and B). Dysmorphic features can be seen: elongated face,
deep-set ears, upturned nose, long philtrum and pointed chin. Parental
written permission has been gained to publish the patient’s photos. T2-
weigthed axial (C) MR image of the patient shows the paucity of white
matter and thinning of the genu of the corpus callosum compared to
age-matched control (E). T1 weighted sagittal MR image of the patient
(D) demonstrates the hypoplasia of the corpus callosum (D) compared
to control (F).
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sive cutis laxa (ADCL3, OMIM 616603 and ARCL3A,
OMIM 219150, respectively) [1–3]. ALDH18A1 encodes
delta-1-pyrroline-5-carboxylate synthetase (P5CS, EC
1.2.1.41 and 2.7.2.11), a mitochondrial bifunctional
enzyme that catalyzes the first two steps in the biosyn-
thesis of proline, ornithine, citrulline, and arginine from
glutamate. It comprises two domains, with different
enzymatic activities: an N-terminal glutamate 5-kinase
(G5K) domain, responsible for the glutamate phospho-
rylation to gamma-glutamyl phosphate, and a C-
terminal glutamate 5-phosphate reductase (G5PR)
domain, which catalyzes the reduction and conversion
to gamma-glutamyl semialdehyde, which is further
metabolized to proline and ornithine [1–3]. Two iso-
forms of P5CS are generated, differing only by 2 amino
acid insert in the G5K domain. The short P5CS isoform
has high activity in gut, where it catalyzes an essential
step in the arginine biosynthetic pathway. The long iso-
form of P5CS is expressed in multiple tissues and is nec-
essary for the synthesis of proline from glutamate [4].
Although P5CS expression in the brain is not strong,
it has a measurable activity [4].
Each of the ALDH18A1-related disorders are rare [1].
We extend the genotypic and phenotypic spectrum of
SPG9B by reporting a girl with compound heterozygous
ALDH18A1 mutations who had intense tremor in
infancy, preceding the development of spastic
paraplegia.
2. Case report
The proband, a girl was born from the first unevent-
ful pregnancy to heathy, non-consanguineous Cau-
casian parents on the 37th gestational week. Her birth
weight was 1950 g (2.2 SD), head circumference
30 cm (2.0 SD) and length 44 cm (1.4 SD). Dysmor-
phic features included elongated face, deep-set ears,
upturned nose, long philtrum and pointed chin
(Fig. 1A, B). She did not have any cutaneous involve-
ment. At about 2 months of age fast head and hand tre-
mor appeared in the form of rhythmic back-and-forth
involuntary movements with low amplitudes both at rest
and during action. Fasting did not worsen these move-
ments. The tremor became quite vigorous with waxing
amplitudes during infancy and gradually waned later.
There was no tremor at rest by the age of 5 years; how-
ever, emotional distress, particularly fear still provoked
it. She had hypotonia and was unable to sit at age of
10 months, or stand at 12 months of age. She had very
short attention span and limited interest in her sur-
roundings. Developmental Quotient (DQ) of 45 was
found by Brunet-Lézine test at the age of 2 years.
Fasting ammonia level was normal. Plasma proline,
ornithine and arginine levels were also within the normal
range, while citrulline level was slightly decreased(9 mmol/L, normal: 10–50 mmol/L, borderline). The
results of other blood tests were normal.
Brain MRI at the age of 2 years revealed reduced vol-
ume of white matter and moderate hypoplasia of the
corpus callosum (Fig. 1C–F).
At the age of 5.5 years her head circumference was
46 cm (3.5 SD), weight 15 kg, (1.9 SD), and height
98 cm (2.8 SD). By this age, marked spasticity through
most of the range of motion (Modified Ashworth scale
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reflexes. Wide based spastic gait was also observed.
There was no speech and intellectual disability was evi-
dent. She had disruptive behavior hindering us from
taking formal Intelligence Quotient (IQ) test.
2.1. Genetic analysis
Routine chromosomal analysis by G-banding showed
normal 46,XX karyotype. Genomic DNA was extracted
from peripheral blood samples with the Puregene kit
(Gentra). Array comparative genomic hybridization
(aCGH) showed normal genomic copy number (Quanti-
tative Genomic Medicine Laboratories, S.L., Barcelona,
Spain).
Trio analysis by whole exome sequencing (WES) was
performed with CentoXome Gold at Centogene AG
(Rostock, Germany) as described earlier [5]. A heterozy-
gous variant in intron 1 (NM_002860.4:c.-28-2A>G)
and another heterozygous variant in exon 4
(NM_002860.4:c.383G>A, NP_002851.2:p.Arg128His)
of the ALDH18A1 gene were detected (Fig. 2A, B).
The c.-28-2A>G variant is likely pathogenic because it
changes the acceptor splice site of intron 1 in the 50-
UTR, causing skipping of exon 2 (the start codon is in
exon 2). The possible molecular effect of this variant
was tested in silico using MutationTaster. It predicted
that c.-28-2A>G variant is disease causing (prob:
0.969300883264394); the wild type splice site (tgca|
GATA c.-28) has been lost. This variant is absent in
the databases [GnomAD (The Genome Aggregation
Database), dbSNP, Exome Variant Server, ClinVar].
However, the p.Arg128His variant has been previously
reported in compound heterozygous state as disease-
causing for autosomal recessive spastic paraplegia [3].
The c.-28-2A>G variant was also detected in the mother
(Fig. 2A) in a heterozygous state, whereas the c.383G>A
was detected in the father (Fig. 2B) also in a heterozy-
gous state.
3. Discussion
The patient in this report is compound heterozygous
for two ALDH18A1 disease-causing mutations. Both
mutations affect the G5K domain of the P5CS enzyme.
The phenotypic characteristics, such as intrauterine
growth retardation, dysmorphic features, short statue,
microcephaly, global developmental delay, cognitive
impairment, progressively developing spastic paraplegia
and lack of cutaneous manifestations in association with
biallelic ALDH18A1 mutations meet the criteria of
SPG9B [1–3,6–8].Fifteen patients in 8 families have been
described so far with this disorder, including the patient
in this report (Table 1). The compound heterozygous
mutations in 5 families and homozygous mutations in
3 families distributed randomly in the ALDH18A1 gene,affecting both the G5K and G5PR domains (Table 1).
Corpus callosum hypoplasia and thin white matter,
found in our patient, have been described in
ALDH18A1-related disorders, however they are rare in
SPG9B (Table 1). Autopsy findings or neuropathology
have never been reported.
The vigorous infantile tremor, the presenting sign in
our patient, was unusual and has never been reported
so early in SPG9B. Tremor, reported in other cases of
SPG9B, started later, at around the 7th and 15th years
of age [2,3] (Table 1). It can be regarded as a manifesta-
tion of neurodegeneration [9]. Tremor has also been seen
in patients with ARCL3 due to biallelic ALDH18A1
mutations [10,11]. Tremor can occur in other types of
hereditary spastic paraplegias as well, like in SPG4
due to SPAST mutation [12] and SPG11 due to muta-
tions in the spatacsin gene [13,14].
Neurodegeneration seems to be a common feature of
autosomal recessive and autosomal dominant
ALDH18A1-related disorders [1]. A unifying view for
these disorders has been hypothesized, claiming that
the different presentations conform to a disease contin-
uum of decreasing severity from the cutis laxa forms
ARCL3A and ADCL3 to the motor syndromes SPG9B
and SPG9A [1]. Global developmental delay and intel-
lectual disability are major manifestations of the central
nervous system involvement with equal frequency in
both autosomal recessive forms, i.e. in ARCL3A and
SPG9B [1]. While hypotonia is a consistent feature in
ARCL3A, occasionally followed by pyramidal signs
[1,10,15], hypotonia seems to be rare in SPG9B; progres-
sive hypertonia, spasticity and pyramidal signs prevail
instead [1,3], as in our patient. A transition between
these autosomal recessive conditions might be repre-
sented by patients reported with biallelic mutations
without both cutis laxa and spastic paraplegia [[16],
Patient 2 in [17]].
Data has been collected and reviewed by Marco-
Marin and coworkers in favor of the view that the sever-
ity of the various syndromes in ALDH18A-related disor-
ders would correspond to higher or lower degrees of loss
of P5CS function [1]. Decreased serum P5CS activity
was found in a patient with SPG9B due to homozygous
p.Ser242Asn mutation in the G5K domain; however, the
P5CS protein level and its mitochondrial localization in
HeLa cells transfected with the mutant ALDH18A1
plasmids remained unchanged [7]. In another patient
with SPG9B due to compound heterozygous mutations
in the G5PR domain of ALDH18A1 (p.Arg371Gln
and p.Ser497Asn) residual activity of the P5CS was also
observed [8]. Indeed, these findings may suggest that the
SPG9B phenotype could be associated with residual
P5CS activity, while some patients with biallelic null
mutations in ALDH18A1 and cutis laxa phenotype
exhibited pronounced reduction or total absence of
P5CS protein [1,11,18,19].
Fig. 2. Mutations in the ALDH18A1 gene. (A) A single nucleotide change (boxed) near the 50 UTR in the mutant compared to normal (wild type)
sequence. The patient inherited this mutation from her mother (R = A/G). (B) A single nucleotide change (boxed) in the exon 4 in the mutant
compared to normal (wild type) sequence. The patient inherited this mutation from her father (R = A/G). The mutated positions are highlighted blue
in the DNA chromatograms. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Table 1
Reported biallelic ALDH18A1 variants associated with autosomal recessive spastic paraplegia (SPG9B).
References This study [6] [2] [3]
Number of affected siblings 1 2 1 4
Gender F M F M F F M F
Ethnicity Caucasian Japanese Japanese Caucasian Caucasian Caucasian Caucasian Caucasian
























































Protein domain G5K/G5K G5K/G5K G5K/G5K G5K/G5PR G5K/G5PR G5K/G5PR G5K/G5PR G5K/G5PR
Dysmorphic features Yes NA NA NA Yes No Yes Yes
Microcephaly Yes NA NA NA Yes Yes No No
Growth retardation Yes NA NA NA Yes Yes No Yes
Developmental delay Yes Yes Yes Yes Yes Yes Yes Yes
Cognitive impairment
Lower limb spasticity Yes Yes Yes Yes Yes Yes Yes Yes
Ataxia No No No No No No No NA
Cerebellar signs
Tremor (age at onset, years) Yes (<1) No No Yes (15) No No No NA
Epilepsy No No No Yes No No No No
Cutaneous findings No No No No No No No No
Ocular findings No No No No NA NA Probable cataract NA
Brain MRI Corpus callosum
hypoplasia
Thin white matter





Plasma amino acids (proline,
citrulline, ornithine, arginine)
Normal NA NA Normal NA NA NA NA





































Reported biallelic ALDH18A1 variants associated with autosomal recessive spastic paraplegia (SPG9B).
References [7] [8] [6] [3]
Number of affected siblings 1 2 2 2
Gender F M M M M M M
Ethnicity Chinese Caucasian Caucasian Japanese Japanese Caucasian Caucasian






































Protein domain G5K G5PR/G5PR G5PR/
G5PR
G5PR/GSPR 5PR/GSPR GSPR GSPR
Dysmorphic features NA Yes Yes NA NA Yes Yes
Microcephaly NA Yes Yes NA NA Yes Yes
Growth retardation NA Yes Yes NA NA NA NA
Developmental delay No Yes Yes Yes Yes Yes Yes
Cognitive impairment
Lower limb spasticity Yes Yes Yes Yes Yes Yes Yes
Ataxia No No No Yes Yes NA No
Cerebellar signs
Tremor (age at onset, years) No No No No No Yes (7) Yes (7)
Epilepsy No Yes Yes No No No No
Cutaneous findings No No No No No No No
Ocular findings No No No No No NA NA







Plasma amino acids (proline, citrulline,
ornithine, arginine)
NA NA NA Normal Normal Normal NA
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levels led to inconstant results. Increased blood ammonia
and low plasma proline, ornithine, citrulline and arginine
were described in both SPG9A and ARCL3A [3,10]. In
contrast, the ammonia and amino acid levels were in
the normal or low normal range in SPG9B patients
regardless of whether the mutation affected the G5K,
as in our case, the G5PR, or both domains [2,3,6]. The
patient population with ALDH18A1-related disorders
is small, hampering the comparison of the sometimes
contradictory results gained by various methods in sin-
gular cases, or families with different phenotypes.
The pathophysiology of the neurological impairment
in ALDH18A-related disorders remains to be clarified.
Reduced cerebral proline and/or creatine synthesis
might have a role [1,19], however moonlighting of
P5CS protein cannot be ruled out [19,20]. Further
research warranted to elucidate the mechanism of neu-
rodegeneration in these conditions.
4. Conclusion
We report a girl with a rare form of autosomal reces-
sive hereditary spastic paraplegia (SPG9B) due to com-
pound heterozygous mutations in the ALDH18A1 gene.
The c.-28-2A>G variant in intron 1 is a novel mutation;
it was inherited from her mother. The other, c.383G>A
variant in exon 4, inherited from her father, has already
been published. Vigorous infantile tremor preceding
progressive spastic paraplegia was a unique clinical
manifestation of the disease. Intrauterine and postnatal
growth retardation, dysmorphic features, microcephaly,
delayed development and intellectual disability were the
other characteristic features of the disorder.Acknowledgments
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